- Home
- QURE
QURE
uniQure N.V.
as 12-20-2024 4:00pm EST
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
| Founded: | 1998 | Country: | Netherlands |
| Employees: | N/A | City: | AMSTERDAM |
| Market Cap: | 750.6M | IPO Year: | 2007 |
| Target Price: | $32.43 | AVG Volume (30 days): | 4.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.73 - $17.71 | Next Earning Date: | 11-05-2024 |
| Revenue: | $28,587,000 | Revenue Growth: | -74.45% |
| Revenue Growth (this year): | 150.65% | Revenue Growth (next year): | -4.57% |
Stock Insider Trading Activity of uniQure N.V. (QURE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kapusta Matthew C | QURE | CEO, Managing Director | Dec 10 '24 | Sell | $15.03 | 100,000 | $1,503,000.00 | 597,915 | |
| Kapusta Matthew C | QURE | CEO, Managing Director | Dec 8 '24 | Sell | $7.63 | 3,418 | $26,079.34 | 597,915 | |
| KLEMT CHRISTIAN | QURE | Chief Financial Officer | Dec 8 '24 | Sell | $7.55 | 1,796 | $13,559.80 | 166,713 |
Latest uniQure N.V. News
QURE Breaking Stock News: Dive into QURE Ticker-Specific Updates for Smart Investing
TipRanks
5 days ago
uniQure price target raised to $32 from $12 at Stifel
Motley Fool
8 days ago
Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?
MT Newswires
10 days ago
Uniqure Insider Sold Shares Worth $1,503,000, According to a Recent SEC Filing
Zacks
11 days ago
QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug
Zacks
11 days ago
Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More
MT Newswires
11 days ago
RBC Raises Price Target on uniQure to $20 From $14, Keeps Outperform, Speculative Risk
MT Newswires
12 days ago
UniQure Gets Rating Upgrade From Wells Fargo After Agreement With FDA -- Shares Continue Rally
Investor's Business Daily
12 days ago
UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug
Compare QURE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "QURE uniQure N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.